The new test can detect antibodies generated from a prior infection or following vaccination against SARS-CoV-2. Credit: NIAID / Flickr.

Rapid Vertical Flow diagnostics manufacturer MedMira has obtained the CE mark for its Covid-19 test, which has been designed to identify the presence of total antibodies.

The REVEALCOVID-19 PLUS Total Antibody Test can detect antibodies that are generated from a prior infection or following vaccination against the SARS-CoV-2 virus.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

MedMira will now launch the test in Europe and other countries that accept the CE mark.

MedMira CEO Hermes Chan said: “We believe the REVEALCOVID-19 PLUS is our next step in Europe to support the healthcare system by allowing a more personalised responsibility approach by offering an easy testing tool and the quickest possible time.

“The use of our REVEALCOVID-19 PLUS will also give a great example of its quality and speed to our customers and open the path further for all our other products.

“During the various independent evaluations, we have received an overwhelming positive response on the quality and handling of our product, and we feel excited to launch this necessary and important product in Europe.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The test, which can be concluded in less than three minutes, is one out of four products for Covid-19 that MedMira has developed and manufactured exclusively at its internationally certified plant.

It provides results instantly and can be used in doctor’s offices and pharmacies due to its ease of use and speed.

In the coming weeks, the company plans to launch its second antibody product in Europe.

Complementing the REVEALCOVID-19 PLUS test, the second product will provide a better understanding of an individual’s potential protection against SARS-CoV-2.